FDG-PET for clinical use: Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000

European Journal of Nuclear Medicine

Volumn 28, Issue 11, 2001, Pages 1707-1723

  Reske, S N ^a   Kotzerke, J ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

FDG; German Consensus Conference; Oncology; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BENIGN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOMA; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; FEMALE; HODGKIN DISEASE; HUMAN; LUNG TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL LITERATURE; NONHODGKIN LYMPHOMA; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034756875     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590100626     Document Type: Article

References (182)

1. Inaugural article: Positron emission tomography provides molecular imaging of biological processes
2. Enzymology of cancer cells (second of two parts)
3. Elevated levels of glucose transport and transporter messenger RNA are induced byras orsrc oncogenes
4. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine
5. Clinical value of positron emission tomography (PET) in oncologic questions: Results of an interdisciplinary consensus conference
6. Positronen-emissions-tomographie in der onkologie
7. Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference
8. Indications for clinical applications of positron emission tomography in cardiology. Position report of the PET Cardiology Study Group of the German Society of Nuclear Medicine and the Nuclear Cardiology Study Circle of the German Society of Cardiology
9. Disease, level of impact, and quality of research methods. Three dimensions of clinical efficacy assessment applied to magnetic resonance imaging
10. How to perform a comprehensive search for FDG-PET literature
11. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology
12. Arbeitsgemeinschaft bevölkerungsbezogener krebsregister in Deutschland
13. 131I whole-body scan
14. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer
15. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study
16. An evaluation of FDG-PET in the detection and differentiation of thyroid tumours
17. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors
18. Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET
19. Improvement in staging of esophageal cancer with the addition of positron emission tomography
20. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography
21. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma
22. 18F-fluorodeoxyglucose positron emission tomography
23. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy
24. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy
25. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies
26. Detection of liver metastases from pancreatic cancer using FDG PET
27. Diagnosis of pancreatic carcinoma: Role of FDG PET
28. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer
29. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases
30. Staging recurrent metastatic colorectal carcinoma with PET
31. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer
32. 18F] fluorodeoxyglucose in management of recurrent colorectal cancer
33. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
34. Evaluation of benign vs malignant hepatic lesions with positron emission tomography
35. Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET
36. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
37. Breast imaging with fluorine-18-FDG PET: Quantitative image analysis
38. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations
39. 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma
40. 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions
41. 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: The experience of the National Cancer Institute of Milan
42. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer
43. 18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation
44. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy
45. Präoperative dignitätsbeurteilung asymptomatischer Adnextumoren mittels positronen-emissions-tomographie und F-18-Fluorodeoxyglukose
46. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
47. Diagnostic value of positron emission tomography for detecting breast cancer
48. Detection of cancer in augmented breasts by positron emission tomography
49. 18F]-D-glucose
50. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours
51. Positron emission tomography in breast cancer: A clinicopathological correlation of results
52. Metabolische charakterisierung von ovarialtumoren mit der positronen-emissions-tomographie und F-18-Fluordeoxyglucose
53. 18F-FDG PET) in diagnosis of ovarian cancer
54. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
55. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
56. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
57. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease
58. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
59. 18F]fluoro-2-deoxy-D-glucose
60. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
61. 18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
62. DGN-Nachrichten: Konsensus - Onko-PET
63. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry
64. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
65. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?
66. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
67. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
68. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
69. Head and neck cancer: Detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET
70. 18FDG PET
71. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography of head and neck in patients with nasopharyngeal carcinomas
72. 18F-fluoro-2-deoxy-D-glucose positron emission tomography
73. 18F-fluorodeoxyglucose indetecting residual/recurrent squamous cell carcinoma of the head and neck
74. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer?
75. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography
76. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting
77. Ist die positronen-emissions-tomographie (PET) zum nachweis tumorbefallener halslymphknoten bei plattenepithelkarzinom des Kopf-Hals-Bereiches in der klinischen Routine sinnvoll einsetzbar?
78. F-18 FDG PET scan after radiotherapy for early-stage larynx cancer
79. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms
80. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography
81. Primary and recurrent early stage laryngeal cancer: Preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging
82. The use of positron emission tomography scanning in occult and recurrent head and neck cancer
83. Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) in the diagnosis and preoperative staging of head and neck tumors: A prospective study
84. Laryngeal radionecrosis versus recurrent cancer: A clinical approach
85. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors
86. Valueof F-18-FDG PET in patients with cervical lymph node metastases of unknown origin
87. FDG PET detection of unknown primary tumors
88. Detection of unknown primary head and neck tumors by positron emission tomography
89. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer
90. Detection of unknown occult primary tumors using positron emission tomography
91. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)
92. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
93. Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment
94. Detection of lymphoma in bone marrow by whole-body positron emission tomography
95. Klinische Wertigkeit der FDG-PET zur Therapiekontrolle bei malignen lymphomen - Ergebnisse einer retrospektiven studie an 72 patienten
96. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
97. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging
98. Extranodal malignant lymphoma: Detection with FDG PET versus CT
99. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow
100. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma
101. 18F]FDG PET in gastric non-Hodgkin's lymphoma
102. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
103. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluoro-deoxyglucose
104. A meta-analysis of the literature of malignant melanoma with whole-body FDG PET
105. Effectiveness of positron emission tomography for the detection of melanoma metastases
106. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma
107. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
108. 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients
109. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients under-going sentinel node biopsy
110. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma
111. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose
112. Klinische wertigkeit der positronen-emissions-tomographie (PET) in der diagnostik der knochen- und weichteiltumore, 3. Konsensuskonferenz 'PET in der onkologie', ergebnisse der arbeitsgruppe knochen- und weichteiltumore
113. FDG-PET in differential diagnosis and grading of chondro-sarcomas
114. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma
115. Tumor metabolic rates in sarcoma using FDG PET
116. Positron emission tomography in grading soft tissue sarcomas
117. FDG-PET for detection of osseous metastases from malignant primary bone tumours: Comparison with bone scintigraphy
118. 18FDG uptake in soft tissue masses
119. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas
120. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography
121. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: Is a non-invasive determination of biological activity possible?
122. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET
123. Metaanalyse zum stellenwertder positronen-emissions-tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei lungentumoren
124. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta-analytic comparison of PET and CT
125. Improvement of non-small-cell lung cancer staging by means of positron emission tomography
126. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging
127. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management
128. Likelihood of malignancy in a solitary pulmonary nodule: Comparison of Bayesian analysis and results of FDG-PET scan
129. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography
130. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET)
131. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease
132. 18F]FDG positron emission tomography (PET)
133. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET
134. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer
135. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography
136. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy
137. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities
138. Pulmonary abnormalities and PET data analysis: A retrospective study
139. Prospective investigation of positron emission tomography in lung nodules
140. 18F]fluorodeoxyglucose in the evaluation of pulmonary nodules
141. Fluorodeoxy-glucose-positron emission tomography in the detection and staging of lung cancer
142. 18F]fluorodeoxyglucose
143. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer
144. 18FDG positron emission tomography in the staging of non-small cell lung cancer
145. Mediastinal staging of non-small-cell lung cancer with positron emission tomography
146. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer
147. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma
148. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients
149. Staging non-small cell lung cancer with whole-body PET
150. 18FDG in patients with bronchogenic carcinoma
151. Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
152. Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling
153. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: Comparison with FDG PET
154. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging
155. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients
156. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: Preliminary prospective evaluation
157. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose
158. 18F-fluorodeoxyglucose positron emission tomography
159. Brain metastases from non-central nervous system tumors: Evaluation with PET
160. Selective use of PET scan in the preoperative staging of NSCLC
161. FDG-PET screening for cerebral metastases in patients with suspected malignancy
162. 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer
163. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
164. Detection of extrathoracic metastases by positron emission tomography in lung cancer
165. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer
166. Detecting recurrent or residual lung cancer with FDG-PET
167. Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-D-glucose
168. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings
169. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma
170. 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer
171. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with at electasis
172. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study
173. A tabulated summary of the FDG PET literature
174. Stadieneinteilung - Eine inter disziplinäre Aufgabe
175. Is screening for breast cancer with mammography justifiable?
176. 14 Years of follow-up from the Edinburgh randomised trial of breast-cancer screening
177. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials
178. Mammography in 53,803 women from the New Hampshire mammography network